Given that disease progression to severe illness in the natural course of COVID-19 typically occurs within 7–14 days after symptom onset, a large number of clinical trials related to IFN were performed at the phase of inflammatory response in the host after a decline in SARS-CoV-2 viral load. The gene discussed is IFNA1; the disease is COVID-19.